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Background and Need for Novel Biomarkers: Brain tumors are the leading cause of death
by solid tumors in children. Although improvements have been made in their radiological
detection and treatment, our capacity to promptly diagnose pediatric brain tumors in their
early stages remains limited.This contrasts several other cancers where serum biomarkers
such as cancer antigen (CA) 19-9 and CA 125 facilitate early diagnosis and treatment.
Aim:The aim of this article is to review the latest literature and highlight biomarkers which
may be of clinical use in the common types of primary pediatric brain tumor.
Methods: A PubMed search was performed to identify studies reporting biomarkers in
the bodily fluids of pediatric patients with brain tumors. Details regarding the sample type
[serum, cerebrospinal fluid (CSF), or urine], biomarkers analyzed, methodology, tumor type,
and statistical significance were recorded.
Results: A total of 12 manuscripts reporting 19 biomarkers in 367 patients vs. 397 controls
were identified in the literature. Of the 19 biomarkers identified, 12 were isolated from CSF,
2 from serum, 3 from urine, and 2 from multiple bodily fluids. All but one study reported
statistically significant differences in biomarker expression between patient and control
groups.
Conclusion:This review identifies a panel of novel biomarkers for pediatric brain tumors. It
provides a platform for the further studies necessary to validate these biomarkers and, in
addition, highlights several techniques through which new biomarkers can be discovered.
Keywords: biomarker, pediatric, brain, tumor, CNS, marker, medulloblastoma
INTRODUCTION
BACKGROUND
Brain tumors are the leading cause of death from solid tumors in
children (1). This statistic, coupled with the rising incidence rate
of pediatric brain tumors from 2.3 cases per 100,000 in 1975 to
3.6 cases per 100,000 in 2009 (1), highlights the need for novel
approaches aimed at tackling these tumors.
Whereas serum biomarkers, such as cancer antigen (CA) 125
and CA 19-9, facilitate the early diagnosis and treatment of several
cancers of adults, few biomarkers exist for pediatric malignan-
cies. Examples include alpha-fetoprotein in hepatoblastomas and
yolk sac tumors, and neuron-specific enolase in neuroblastomas.
Biomarkers of pediatric brain tumors remain elusive however,
with the exception of alpha-fetoprotein and β-human chorionic
gonadotropin in intracranial germ cell tumors (2, 3).
BIOMARKERS AND THEIR CLINICAL USE
A tumor biomarker is a substance, measureable in cancer patients,
whose detection reflects the presence of a tumor (4). One clinical
Abbreviations: AT/RT, atypical teratoid/rhabdoid tumor; bFGF, basic fibroblast
growth factor; CNS, central nervous system; CSF, cerebrospinal fluid; ELISA,
enzyme-linked immunosorbent assay; IGF, insulin-like growth factor; IGFBP,
insulin-like growth factor-binding protein; MMP,matrix metalloproteinase; PGD2S,
prostaglandin D2 synthase; PSA-NCAM, polysialic-neural cell adhesion molecule;
VEGF, vascular endothelial growth factor.
use for tumor biomarkers is in the screening of asymptomatic
populations for occult tumors. Despite a rising incidence rate,
pediatric brain tumors remain relatively uncommon. As such,
mass screening of asymptomatic children using novel biomarkers
is unlikely to be cost-effective at present. Fluid analysis for novel
biomarkers could, however, facilitate the timely diagnosis of chil-
dren in whom there is a clinical suspicion of a brain neoplasm.
Furthermore, an early histological diagnosis may be made possible
by analysis for biomarkers specific to particular types of pediatric
brain tumor. This would help direct pre-operative management,
such as chemotherapy and radiotherapy, as well as aid prognos-
tication. Following treatment, serial measurement of biomarker
levels could also be used to monitor treatment response and detect
recurrence.
CURRENT CHALLENGES
A likely contributing factor to the paucity of biomarkers in the
serum of pediatric brain tumor patients is the blood-brain bar-
rier. The cerebrospinal fluid (CSF) has thus been investigated as
an alternative diagnostic fluid to serum in the search for pedi-
atric brain tumor markers. Numerous CSF biomarkers of pediatric
brain tumors were highlighted in literature reviews published in
the 1980s (5). Perhaps the most promising were polyamines in
children with medulloblastomas. One study demonstrated consis-
tent elevations in CSF levels of putrescine, a polyamine, in 32
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children with medulloblastomas relative to controls (6). Many
other candidates were too non-specific for routine clinical use,
however.
Moreover, the value of urine as an alternative diagnostic fluid
to serum and CSF is already well established in the case of
one pediatric malignancy. In neuroblastomas, quantification of
urinary catecholamine metabolites facilitates disease diagnosis,
with a reported specificity and sensitivity of >99 and 66–100%,
respectively (7).
AIMS
The search for biomarkers in the serum, CSF, and urine of pedi-
atric brain tumor patients has continued in recent years. We review
the latest literature and highlight those biomarkers which may be
of clinical use in the common types of primary pediatric brain
tumor. By identifying such biomarkers we hope to facilitate the
prompt diagnosis and treatment of novel and recurrent disease
through minimally invasive means.
METHODS
A PubMed search was performed to identify studies reporting
biomarkers in the prevalent forms of primary pediatric brain
tumor. The following terms were combined along with appropri-
ate synonyms, abbreviations, and MeSH terms: “serum,”“plasma,”
“blood,”“CSF,”“urine,”“biomarker,”“marker,”“pediatric,”“brain,”
“central nervous system (CNS),” “tumor,” “neoplasm,” “medul-
loblastoma,” “glioma,” “pilocytic,” “astrocytoma,” “primitive neu-
roectodermal,”“craniopharyngioma,”“atypical teratoid,”“ependy-
moma.”
The search was limited to manuscripts published since 1990.
Studies reporting biomarkers in the serum, CSF, and urine of
pediatric brain tumor patients that were differentially expressed
relative to controls were selected. For each study selected, the num-
ber and age of patients and controls was recorded along with details
regarding the biomarkers being analyzed, the diagnostic fluid cho-
sen, patient tumor types, quantification methodologies, and any
outcome measures reported.
RESULTS
Twelve studies were identified, highlighting a total of 19
biomarkers in 367 tumor patients vs. 397 controls (Table 1).
The biomarkers from all but one study were able to discriminate
between tumor patients and controls to a statistical significance of
p≤ 0.05. In the remaining study, the authors did not specify the
statistical significance of their findings (8).
Of the 19 biomarkers reported, 12 were biomarkers in CSF
alone, 2 in serum alone, 3 in urine alone, 1 in CSF and plasma, and
1 in CSF and urine. A wide range of techniques were used to detect
and quantify the biomarkers, with enzyme-linked immunosorbent
assays (ELISA), western blots, and radioimmune assays being the
most frequently used. The majority of studies included a vari-
ety of CNS tumors in patient cohorts. Only two studies included
tumors from outside the CNS within the patient cohort (8, 9). In
both cases, the authors separated these tumors from those of CNS
origin during subsequent analysis.
In all but one study, patient cohorts were of a pediatric/young
adult age range. The remaining study included both adult and
pediatric patients but proceeded to analyze the two age groups
separately (10). The control cohort used in this study also included
both children and adults, but again, these groups were separated
during further analysis. All other studies used only controls of a
young age, apart from one study which compared pediatric tumor
patients to healthy adult controls (9).
DISCUSSION
URINARY MATRIX METALLOPROTEINASES
Matrix metalloproteinases (MMPs) are degradative enzymes with
central roles in tumor neovascularization, invasion, and metas-
tasis. Several MMPs are known to be overexpressed in primary
brain tumors (11). This, coupled with the detection of MMPs in
the urine of patients with a variety of cancers (12–15) prompted
the investigation of their utility as urinary biomarkers of brain
tumors (10). In this study, MMP-2, MMP-9, and MMP-9/NGAL,
in addition to the pro-angiogenic molecule vascular endothelial
growth factor (VEGF), were found to be elevated in the urine of
28 brain tumor patients relative to controls (p< 0.001). Although
the cohort of brain tumor patients contained both children and
adults, the elevations remained statistically significant on analy-
sis of the 11 pediatric patients alone. With optimal cut-off levels,
MMP-2 and VEGF had sensitivities of 82.1 and 95.2% and speci-
ficities of 95.7 and 89.5%, respectively, in differentiating tumor
patients from controls.
During the longitudinal follow-up of a subset of patients, the
authors observed clearance of the biomarkers following tumor
resection. When coupled with their demonstration of a correlation
between overexpression of MMPs and VEGF in tumor specimens
and their presence in urine, these findings suggest a tumor-source
for the urinary biomarkers.
The authors also noted elevations of MMP-9 in the CSF of brain
tumor patients relative to controls (p< 0.05). This is in keeping
with the results of a previous study, which detected MMP-9 in the
CSF of 10/15 adult brain tumor patients with positive CSF cytol-
ogy, compared to 0/27 controls (16). Interestingly, this study also
found pro-MMP-9, the precursor of MMP-9, to be detectable in
the CSF of all 39 brain tumor patients irrespective of CSF cytology
status but in none of the controls. The potential utility of MMP-9
as a biomarker in urine and CSF contrasts the results of a recent
study investigating MMP-9’s role as a serum biomarker of gliomas
(17). In this study, the longitudinal monitoring of serum MMP-9
concentrations was not found to correlate with survival or disease
status.
APOLIPOPROTEIN A-II
SELDI-TOF mass spectrometry was used by de Bont et al. to com-
pare the protein expression profiles of CSF samples obtained from
32 pediatric patients with a wide range of brain tumors and 70
pediatric controls (18). Of the protein peak clusters found to be
differentially expressed between the two groups, apolipoprotein
A-II was found to be highly significant (p< 0.0001) and double-
loop classification analysis of the differentially expressed protein
clusters demonstrated a mean prediction accuracy and specificity
of 88% in separating brain tumor patients from controls. The
high CSF/blood albumin concentration ratio and lack of cellular
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Table 1 | Reports in the literature describing fluid biomarkers of pediatric brain tumors.
Authors Year Biomarker(s) Sample type(s) Methodology n Tumor type(s) Findings pValue
Smith et al.
(10)
2008 MMP-2,-9,-
9/NGAL and
VEGF
Urine, CSF ELISA,
zymography
51 Various CNS
tumors
Elevations in urinary
MMP-2, -9, -9/NGAL and
VEGF in tumor patients.
MMP-9 elevated in CSF of
tumor patients
<0.001 (Urine),
<0.05 (CSF)
de Bont et al.
(18)
2006 Apolipoprotein
A-II
CSF MS, WB 102 Various CNS
tumors
Overexpressed in tumor
patients
<0.0000001
Li et al. (19) 1994 bFGF CSF ELISA 44 Various CNS
tumors
Detectable in 16/26 tumor
patients, but not in
controls
<0.0001
Rajagopal et
al. (20)
2011 PGD2S, Apo E
and J
CSF 2D-
electrophoresis,
MS, ELISA
58 Medullo. PGD2S and Apo E
reduced, and Apo J
increased, in tumor
patients
<0.00001
(PGD2S), <0.01
(Apo E and J)
de Bont et al.
(22)
2008 IGFBP-3,4,6 Blood, CSF Radioimmune
assay
62 Medullo.,
ependy.
IGFBP-3, -4, -6 elevated in
the CSF, but not blood, of
medulloblastoma patients
<0.001/=0.011/
=0.010
Müller et al.
(23)
1993 IGFBP-3 Serum, CSF Radioimmune
assay, WB
61 Various CNS
tumors
Elevated in CSF, but not
serum, of 16/23 tumor
patients, incl. 12/13
medullo./ependy. patients
<0.0001
Müller et al.
(24)
1994 IGFBP-2 Serum, CSF Radioimmune
assay, WB, IP
67 Various CNS
tumors
Elevated in CSF, but not
serum, of tumor patients
<0.001
Figarella-
Branger et al.
(28)
1996 PSA-NCAM CSF ELISA 43 Medullo. Concentrations greater in
treatment-refractory and
relapsing patients than
patients in remission or
controls
<0.05
de Bont et al.
(29)
2008 t-Tau, p-Tau(181P) CSF IP 61 Various CNS
tumors
t-Tau and p-Tau(181P)
increased and decreased
in tumor patients,
respectively
<0.001 (=0.002
for t-Tau in
non-medullo.)
Kao et al. (35) 2005 Osteopontin Plasma, CSF ELISA 39 AT/RT,
medullo.
Elevated in the CSF and
plasma of AT/RT patients
<0.05
Krizkova et al.
(9)
2010 Metallothionein Serum DVP, WB 96 Solid tumors Elevated in cancer
patients’ sera, incl. that of
medullo. and ependy.
patients
<0.05
Behrends
et al. (8)
2003 Humoral
responses
Serum cDNA libraries,
plaque assays
80 Various
cancers
Humoral responses to
several medullo. antigens
noted exclusively/
predominantly in cancer
patients.
Not specified
See text for individual details. p Value significant if p<0.05. WB, western blot; MS, mass spectrometry; IP, immunoprecipitation; DVP, differential pulse voltammetry;
ELISA, enzyme-linked immunosorbent assay.
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apolipoprotein A-II staining in tumor patients led the authors to
conclude that the elevated apolipoprotein A-II levels resulted from
entry from blood into the CSF across a leaky blood-brain barrier
as opposed to increased tumor production.
BASIC FIBROBLAST GROWTH FACTOR
In view of the abundant neovascularization present in brain
tumors, one group analyzed levels of basic fibroblast growth
factor (bFGF), a pro-angiogenic molecule, in the CSF of 26
pediatric and adolescent brain tumor patients (19). bFGF was
found to be detectable in 16 of the 26 brain tumor patients
but no controls (p< 0.0001). Furthermore, the concentration of
bFGF in CSF samples correlated with the microvessel density
of tumor sections from the same patients (p< 0.005), which,
in turn, was associated with tumor recurrence (p= 0.005) and
mortality (p= 0.02). The authors concluded that bFGF may be
an important angiogenic mediator in brain tumors and thus a
novel therapeutic target, as well as a diagnostic and prognostic
biomarker.
PROSTAGLANDIN D2 SYNTHASE AND APOLIPOPROTEINS E AND J
In a recent study, CSF samples from 33 children with medul-
loblastomas were analyzed using two-dimensional electrophore-
sis and mass spectrometry (20). This demonstrated a sixfold
mean reduction in prostaglandin D2 synthase (PGD2S) levels
in medulloblastoma patients relative to age-matched controls
(p< 0.00001). Similarly, the authors reported a nearly eightfold
reduction in PGD2S concentration in tumor patients when quan-
tified using ELISA (p< 0.000002). The CSF levels of apolipopro-
teins E and J were also noted to be different in medulloblastoma
patients relative to controls, albeit less significantly, with a twofold
reduction and three-fold elevation, respectively (p< 0.01 in both
cases).
INSULIN-LIKE GROWTH FACTOR PATHWAY
In view of the likely role played by the insulin-like growth factor
(IGF) system in the development of CNS neoplasms (21), several
studies have investigated their utility as biomarkers of pediatric
brain tumors.
In one study, radioimmune assays were used to determine the
protein levels of various components of the IGF pathway in the
blood and CSF of children with medulloblastomas and ependymo-
mas (22). Insulin-like growth factor-binding protein-3 (IGFBP-3)
showed most promise as a biomarker. Relative to age- and gender-
matched controls, median levels of IGFBP-3 were significantly
higher in the CSF, but not blood, of children with medulloblas-
tomas (p< 0.001). Protein levels of IGFBP-4 and IGFBP-6 were
also noted to be significantly elevated in the CSF of medul-
loblastoma patients (p= 0.011 and p= 0.010, respectively). When
corrected for total CSF protein content,however,only IGFBP-3 ele-
vations remained statistically significant relative to controls. The
findings of de Bont et al. are in line with those of an earlier study, in
which elevations of IGFBP-3 were found in the CSF, but not serum,
of 16 out of 23 children with CNS neoplasms (p< 0.0001) (23).
A separate study by Müller et al. investigated IGFBP-2 as a bio-
marker in 21 children with malignant CNS tumors (24). IGFBP-2
was significantly elevated in the CSF, but not serum, of children
with CNS tumors (p< 0.001), contrasting the findings of de Bont
et al. who failed to show elevations in IGFBP-2 in the CSF of
medulloblastoma and ependymoma patients (22). de Bont et al.
note, however, that Müller et al. failed to correct for total CSF
protein count and thus a non-specific elevation of protein in the
CSF cannot be excluded.
POLYSIALIC-NEURAL CELL ADHESION MOLECULE
Polysialic-neural cell adhesion molecule (PSA-NCAM) is a cell-
surface glycoprotein, transiently expressed in the developing brain
but not in mature cells (25). PSA-NCAM is re-expressed in
tumors of neuroectodermal origin, including medulloblastomas,
and its presence in the CSF of several medulloblastoma patients
appears to correlate with invasion of the meninges by the tumor
(26, 27).
One study investigated PSA-NCAM’s role as a biomarker of
meningeal invasion in the follow-up of patients with medul-
loblastoma (28). ELISA was used to quantify the concentra-
tion of PSA-NCAM in samples of CSF taken at various points
in the follow-up of 29 children with medulloblastomas. In
treatment-refractory and relapsing patients, PSA-NCAM concen-
trations were significantly higher than in patients in remission
(p< 0.05), with concentrations undetectable in the CSF of con-
trols. Of the eight medulloblastoma patients with persistently
elevated PSA-NCAM levels all but one were refractory to treat-
ment and all eight patients died during follow-up. Of the 12
medulloblastoma patients with persistently undetectable PSA-
NCAM, 11 achieved first remission and lived to the end of
the follow-up period. PSA-NCAM may therefore have a role
in the staging, prognostication, and ultimately management of
medulloblastomas.
TAU
Tau is a group of microtubule-associated proteins found pre-
dominantly within neurons. Working on the hypothesis that
neurodegeneration is likely to occur during brain tumor evo-
lution, one group analyzed levels of total-Tau (t-Tau) and
hyperphosphorylated-Tau(181P) [p-Tau(181P)] in the CSF of 22
children with newly diagnosed brain tumors using monoclonal
antibodies (29).
When compared to pediatric controls, t-Tau was significantly
elevated in the CSF of children with both medulloblastomas
(p< 0.001) and other types of brain tumor (p= 0.002); indicative
of neuronal and axonal degeneration. Conversely, CSF levels of
p-Tau(181P) were significantly lower than controls, both in cases
of medulloblastoma (p< 0.001) and other brain tumor types
(p< 0.001). The authors speculate whether this reflects an increase
in phosphatase activity in tumor patients.
OSTEOPONTIN
Osteopontin is a bone matrix glycoprotein overexpressed in
numerous cancers and implicated in several tumorigenic processes
(30, 31), including via the induction of MMPs (32, 33).
Following their demonstration that the osteopontin gene and
its protein product are up-regulated in primary cell cultures and
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tumor specimens from CNS atypical teratoid/rhabdoid tumors
(AT/RTs) (34), Kao et al. investigated the osteopontin protein
product as a fluid biomarker of CNS AT/RTs (35). Using ELISA,
the median osteopontin levels were shown to be significantly ele-
vated in the plasma and CSF of children with CNS AT/RTs, relative
to medulloblastoma patients and controls (p< 0.05). Moreover,
elevations in osteopontin correlated inversely with patient sur-
vival time (p< 0.0001, plasma; p= 0.0003, CSF). Further analysis
of five AT/RT cases found that plasma osteopontin levels decline
on tumor remission and increase on tumor relapse (p< 0.05).
The authors went on to demonstrate amplification of osteopon-
tin transcripts in AT/RT tumor specimens, supporting increased
tumor production as the source of elevated osteopontin protein
levels in the plasma and CSF.
METALLOTHIONEIN
Metallothioneins are a family of intracellular proteins implicated
in several aspects of oncogenesis (36). In a recent study, metal-
lothionein levels were quantified in the sera of 38 children with
a variety of newly diagnosed solid tumors (including 10 medul-
loblastomas and 4 ependymomas) using differential pulse voltam-
metry (9). When compared to controls, a fivefold elevation in
serum metallothionein levels was noted in children with cancer
(p< 0.05). When analyzed separately, serum metallothionein lev-
els were significantly elevated in both the medulloblastoma and
ependymoma groups (p< 0.05). It should be noted, however, that
the controls used in this study were healthy adults rather than chil-
dren. Given the numerous metallothionein isoforms with variable
tissue distributions, further investigation is needed to elucidate
whether any isoforms in particular are elevated relative to others;
as eluded to by the authors.
HUMORAL RESPONSES TO MEDULLOBLASTOMA ANTIGENS
Working on the principle that cancer patients may develop
immune responses to tumor antigens, Behrends et al. investi-
gated tumor-specific humoral responses as novel biomarkers of
pediatric brain tumors (8). Using autologous sera, the authors
screened the cDNA expression libraries of four medulloblas-
tomas, highlighting 15 antigens of interest. Sera from 40 chil-
dren with cancer, including 20 cancers of neuroectodermal ori-
gin, were then analyzed for humoral responses against each of
the 15 antigens using plaque assays, and compared to healthy
controls.
Humoral responses against five of the antigens were found
exclusively in cancer patients, with frequencies ranging from 2/40
to 7/40 patients. Antibodies against two of these antigens were
present in the sera of 2/5 medulloblastoma patients but in no
controls. Two of the remaining 10 antigens had antibodies in the
sera of 8/40 and 12/40 cancer patients but in only one control.
This included 3/5 and 2/5 medulloblastoma patients, respectively,
in addition to 1/2 astrocytoma patients in both cases. As the
authors point out, immune responses against a homolog of the
latter antigen, GLEA2, had previously been demonstrated in a
study of glioma patients (37). In this study, anti-GLEA2 humoral
responses were present in 20/50 glioma patients but in only 2/14
controls.
CONCLUSION
SUMMARY
Brain tumors are the leading cause of solid tumor mortality in
children. At present, no biomarkers exist for the prevalent forms
of pediatric brain tumor. Their discovery could facilitate disease
diagnosis, prognostication, management and follow-up, and may
ultimately improve survival. Through a literature search, this study
identifies 19 candidate biomarkers, all but one of which separated
tumor patients from controls to a statistically significant degree.
The majority of these biomarkers were identified from sin-
gle studies with widely varying cohorts and heterogeneous tumor
types. Subsequently, there has been no apparent effort to vali-
date these findings in second populations or to incorporate the
biomarkers into prospective clinical trials. Although promising,
it is not therefore possible to draw firm conclusions on the
biomarkers’ clinical utility based on these studies alone.
This review highlights the pressing need for further study
in a field that has had little study so far. Moreover, it pro-
vides a platform for subsequent study by identifying a panel of
novel biomarkers warranting further investigation and an array of
techniques through which this panel can be expanded upon.
FUTURE DIRECTIONS
Studies to validate the biomarkers presented here will require
multi-center collaboration to increase cohort numbers and homo-
geneity. The separation of patient cohorts by tumor histology
will help identify tumor type-specific biomarkers, facilitating
early histological diagnoses and aiding both prognostication and
pre-operative management.
Of note, several of the biomarkers identified here originate from
processes such as blood-brain barrier disruption, neurodegener-
ation, extracellular matrix remodeling, and angiogenesis. These
processes are by no means tumor-specific, and the inclusion of
control cohorts such as stroke or trauma patients in subsequent
studies will help determine the biomarkers’ specificity for tumors.
The choice of quantification technique and diagnostic fluid for
further studies will need careful consideration of cost- and time-
efficiency if the biomarkers are to enter the clinical arena. Urine is
particularly appealing as a diagnostic fluid given the relative ease
and low cost of its collection and analysis (10); especially true when
compared to the expense and need for sedation in many pediatric
imaging studies.
Novel avenues for biomarker discovery must be also inves-
tigated. A prime example is the recent detection of exosomes
containing tumor-specific proteins, mRNA, and microRNAs in
the sera of glioblastoma patients (38). As the authors state, nucleic
acids carry great potential as biomarkers, both due to the avail-
ability of polymerase chain reaction as a highly sensitive means
of detection and the presence of tumor-specific mutations such as
EGFRvIII.
Finally, the application of multi-analyte profiling technology to
the study of pediatric brain tumors could assist both biomarker
discovery and validation. Multi-analyte profiling permits high-
throughput screening of diagnostic fluids against large panels of
biomarkers and has already advanced knowledge of biomarkers in
a number of other conditions (39).
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